Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ: HRMY )

38.98 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harmony Biosciences Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Harmony Biosciences Holdings, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – HRMY
From The Rosen Law Firm, P.A.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
HRMY Stock Alert: Scorpion Short Report Sends Harmony Plunging
Scorpion Capital has issued a short report on HRMY stock, alleging that the company's Wakix drug is not safe for the public. 
Via InvestorPlace
Stocks Mixed After Upbeat Consumer Confidence Data
The Dow Jones Industrial Average managed to swing into positive territory this afternoon, though the S&P 500 Index and Nasdaq Composite Index are still sitting in the red. 
Via Talk Markets
Dow Rises 50 Points; Harmony Biosciences Shares Plunge
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 50 points on Tuesday. The Dow traded up 0.16% to 32,484.24 while the NASDAQ fell 0.75% to 11,681.12. The S&P 500, also... 
Via Benzinga
EXCLUSIVE: Harmony Bio Responds To Short Report, Tells Benzinga It Disagrees With Assertions
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) shares fell almost 20% after Scorpion Capital filed a Citizen's Petition with the FDA requesting the withdrawal of approval of Wakix (pitolisant). 
Via Benzinga
Nasdaq Down Over 50 Points; US Goods Trade Deficit Widens Slightly
U.S. stocks traded mixed this morning, with the Nasdaq Composite dropping around 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.01% to 32,436.22 while the NASDAQ fell... 
Via Benzinga
The Latest Analyst Ratings for Harmony Biosciences
Via Benzinga
With This Big Transition Ahead, Is Novavax a Buy?
Novavax stock sank 92% last year. 
Via The Motley Fool
Short Seller Report On Harmony Biosciences: Here's Why The Stock Is Tanking
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) shares are trading lower after Scorpion Capital filed a Citizen's Petition with the FDA requesting the withdrawal of approval of Wakix (pitolisant). 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023. 
Via InvestorPlace
Harmony Biosciences (HRMY) Q4 2022 Earnings Call Transcript
HRMY earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Harmony Biosciences, The No. 3 Biotech, Just Topped Forecasts; But Concerns Persist
The company offered neither financial guidance nor plans for a new CEO. 
Via Investor's Business Daily
Big Retailers Report
Good Morning Everyone! Customers are setting banks on fire in Lebanon because they can’t get their money out. Inflation is at +170%. This is what a currency collapse looks like: 
Via Benzinga
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
From Harmony Biosciences
Via GlobeNewswire
Alkermes Stock Sees Rising Relative Price Strength
The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86. 
Via Investor's Business Daily
Anavex Life Sciences Stock Shows Improved Price Strength Rating
Anavex Life Sciences stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 75. 
Via Investor's Business Daily
The 7 Best Biotech Stocks to Buy for February 2023
Following the wave of red ink last year, astute investors should target the best biotech stocks to buy this month for strong growth potential. 
Via InvestorPlace
7 Healthcare Stocks That Will Be Big Winners in 2023
Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider. 
Via InvestorPlace
If You Invested $1,000 in Novavax In 2020, This Is How Much You Would Have Today
The stock has gone on a wild ride over the past few years. 
Via The Motley Fool
2 Biotechs Making Waves With A Single Product in their Pipeline
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise. 
Via MarketBeat
NVAX Stock Alert: What to Know as Novavax Names New CEO
Although a change at the top boosted sentiment for Novavax, the harsh reality is that NVAX stock faces a mountain of worries. 
Via InvestorPlace
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
Moderna Stock Shows Surprising Strength; Key Rating Upgraded
See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average. 
Via Investor's Business Daily
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating
On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier. 
Via Investor's Business Daily
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier. 
Via Investor's Business Daily
BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84
The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS